TScan Therapeutics, Inc. (TCRX) AI Dilution Summary

TCRX is funding itself from its balance sheet: estimated cash was $100,156,000 as of 2026-06-30, matching the $100,156,000 reported at the 2026-06-30 balance-sheet date, against estimated monthly burn of $9,178,333. Dilution here is driven primarily by S-3 shelf 333-285570, registered to $300,000,000 with $300,000,000 remaining and $16,656,874.40 currently available under I.B.6, expiring 2028-03-14.